«ÉÏһƪ/Previous Article|±¾ÆÚĿ¼/Table of Contents|ÏÂһƪ/Next Article»

¡¶ÐÄÔàÔÓÖ¾¡·[ISSN:1009-7236/CN:61-1268/R]

ÆÚÊý:

2006ÄêµÚ2ÆÚ

Ò³Âë:

201-204

À¸Ä¿:

ÁÙ´²Ñо¿

³ö°æÈÕÆÚ:

2006-03-01

ÎÄÕÂÐÅÏ¢/Info

Title:

Serum oxidized low density lipoprotein level is an independent predictor of severity of coronary heart disease

×÷Õß:

½ðÕñÏþ¹; ÕÔÀÙ²; Ñ¦ÎÀ±ó¹; ÐÁ÷¹; ÐìÑ໪³; Ò׶¨»ª¹

µÚËľüÒ½´óѧÎ÷¾©Ò½Ôº£º1.ÐÄѪ¹ÜÍâ¿ÆÖÐÐÄ£¬2. ¹ú¼ÒÁÙ´²Ò©Àí»ùµØ£¬ÉÂÎ÷ Î÷°² 710032£»3.³É¶¼»ªÉñ¼¯ÍÅÉúÎïÖÆÒ©ÓÐÏÞ¹«Ë¾£¬ËÄ´¨ ³É¶¼ 610225

Author(s):

JIN Zhen-xiao¹;  ZHAO Lei²;  XUE Wei-bin¹;  XIN Mei¹; XU Yan-hua³;  YI Ding-hua¹

1.Institute of Thoracic and Cardiovascular Surgery, 2.National Drug Clinical Trial Base, Xijing Hospital, Fourth Military Medical University, Xi¡äan, Shaanxi 710032, China£» 3.Chengdu Hosit Bioª²Pharmacy Co., LTD. Chengdu, Sichuan 610225, China

¹Ø¼ü´Ê:

¹Ú×´¶¯Âö¼²²¡; ¹Ú×´¶¯ÂöÔìÓ°; µÍÃܶÈÖ¬µ°°×; Ñõ»¯; Ã¸ÁªÃâÒßÎü¸½ÊÔÑé

Keywords:

coronary artery disease;  coronary artery angiography;  low density lipoprotein;  oxidized;  enzyme linked immune absorption assay (ELISA)

·ÖÀàºÅ:

R654.2

DOI:

-

ÎÄÏ×±êʶÂë:

A

ÕªÒª:

Ä¿µÄ Ñо¿Ñª½¬Ñõ»¯µÍÃܶÈÖ¬µ°°×£¨OxLDL£©Ë®Æ½Óë¹ÚÐIJ¡ÑÏÖس̶ȵĹØϵ¡£·½·¨ 134Àý»³ÒÉΪ¹ÚÐIJ¡µÄסԺ»¼Õߣ¬½øÐÐÑ¡ÔñÐÔ¹Ú×´¶¯ÂöÔìÓ°¡£¸ù¾Ý¹ÚÂöÔìÓ°½á¹û£¬½«»¼Õß·ÖΪ¹ÚÐIJ¡×飨113Àý£¬ÖÁÉÙÓÐ1Ö§¹ÚÂöÏÁÕ­¡Ý50%£©ºÍ¶ÔÕÕ×飨21Àý£¬ËùÓйÚÂö·ÖÖ§ÏÁÕ­¾ù<50%£©¡£¹ÚÐIJ¡×é°´ÕÕ¹ÚÂö²¡±äÖ§Êý½øÒ»²½·ÖΪ4¸öÑÇ×飨1Ö§²¡±ä26Àý£¬2Ö§²¡±ä26Àý£¬3Ö§²¡±ä53Àý£¬4Ö§²¡±ä8Àý£©£»°´ÕÕ·¢²¡Ö¢×´·ÖΪÎȶ¨ÐÍÐĽÊÍ´×飨51Àý£©¡¢²»Îȶ¨ÐÍÐĽÊÍ´×飨22Àý£©ºÍ¼±ÐÔÐļ¡¹£ËÀ×飨40Àý£©¡£Ñª½¬OxLDLˮƽ²ÉÓÃELISAÊÔ¼ÁºÐ¼ì²â¡£ÆäËû¹ÚÐIJ¡Î£ÏÕÒòËØÈçÄêÁä¡¢ÐÔ±ð¡¢ÌåÖÊÁ¿Ö¸Êý¡¢ÑªÖ¬µÈÊý¾ÝÒ²Ò»²¢ÊÕ¼¯¡£½á¹û ÔÚ¹ÚÐIJ¡×éºÍ¶ÔÕÕ×éÖ®¼ä£¬³ýÁ˸ßѪѹ²¡Ê·ÓÐÏÔÖøÉý¸ßÍâ(46% vs 19%, P<0.05)£¬ÆäËûÖ¸±êûÓÐÏÔÖø²î±ð¡£¹ÚÐIJ¡»¼ÕßѪ½¬OxLDLˮƽÏÔÖø¸ßÓÚ¶ÔÕÕ×飨1.15¡À0.32£© ¦Ìkat/ml vs £¨0.68¡À0.30£© ¦Ìkat/ml£¬P<0.01£©¡£1~4Ö§²¡±ä¹ÚÐIJ¡»¼Õߣ¬ÆäѪ½¬OxLDLº¬Á¿¾ùÏÔÖø¸ßÓÚ¶ÔÕÕ×飨1.10¡À0.32£© ¦Ìkat/ml¡¢£¨1.12¡À0.27£© ¦Ìkat/ml¡¢£¨1.17¡À0.32£© ¦Ìkat/mlºÍ£¨1.33¡À0.37£© ¦Ìkat/ml vs £¨0.68¡À0.30£© ¦Ìkat/ml£¬P<0.01£©£»µ«²»Í¬Ö§Êý²¡±ä»¼ÕßÑÇ×é¼äÎÞÏÔÖøÐÔ²îÒì¡£Îȶ¨ÐÍÐĽÊÍ´¡¢²»Îȶ¨ÐÍÐĽÊÍ´ºÍ¼±ÐÔÐļ¡¹£ËÀ»¼ÕßѪ½¬OxLDLº¬Á¿¾ùÏÔÖø¸ßÓÚ¶ÔÕÕ×飨1.13¡À0.30£© ¦Ìkat/ml£¬£¨1.23¡À0.33£© ¦Ìkat/mlºÍ£¨1.15¡À0.32£© ¦Ìkat/ml vs £¨0.68¡À0.30£© ¦Ìkat/ml£¬P<0.01£©£»µ«ÊǸ÷·Ö×éÖ®¼äÎÞÏÔÖøÐÔ²îÒì¡£ÒÔѪ½¬OxLDLˮƽΪÒò±äÁ¿½øÐжàÔª»Ø¹é·ÖÎö£¬·¢ÏÖ¹ÚÂö²¡±äÖ§ÊýÊÇѪ½¬OxLDLˮƽÉý¸ßµÄ¶ÀÁ¢Î£ÏÕÒòËØ£¨P<0.01£©¡£½áÂÛ Ñª½¬OxLDLˮƽÊǹÚÐIJ¡ÑÏÖس̶ȶÀÁ¢Ô¤±¨ÒòËØ¡£

Abstract:

AIM To investigate the relationship between serum oxidized low density lipoprotein (OxLDL) level and the severity of coronary artery disease (CAD). METHODS One hundred and thirty four suspected CAD inª²hospital patients were recruited in this study. All the patients had selected coronary artery angiography (CAG). According to the CAG results, the patients were divided into CAD group (113 cases, with at least one vessel stenosis ¡Ý50%) and control group (21 cases, with all coronary artery stenosis <50%). The CAD group was further divided into four subgroups: 1 vessel diseased group (26 cases), 2 vessels diseased group (26 cases), 3 vessels diseased group (53 cases) and 4 vessels diseased group (8 cases). Or according to the clinical symptoms, the CAD group was divided into 3 subgroups: stable angina pectoris (SAP) group (51 cases), unstable angina pectoris (UAP) group (22 cases) and acute myocardial infarction (AMI) group (40 cases). Serum OxLDL levels were detected with ELISA method. Other CAD related risk factors including age, sex, body mass index (BMI) and serum lipids levels were also examined. All these factors were statistically analyzed and their relationship with the severity of CAD was evaluated. RESULTS There were no significant differences between CAD group and control group in the above clinical CAD risk factors, except that the hypertension history ratio in CAD group was significantly higher than that in control group (46% vs 19%, P<0.05). The serum OxLDL concentration in CAD group was much higher than that in control group (1.15¡À0.32£© ¦Ìkat/ml vs £¨0.68¡À0.30£© ¦Ìkat/ml; P<0.01). The 1-4 vessels diseased subgroups also had a significantly higher serum OxLDL concentrations compared with those in control group (1.10¡À0.32£© ¦Ìkat/ml, £¨1.12¡À0.27£© ¦Ìkat/ml, £¨1.17¡À0.32£© ¦Ìkat/ml and £¨1.33¡À0.37£© ¦Ìkat/ml vs £¨0.68¡À0.30£© ¦Ìkat/ml, P<0.01, but there was no significant difference among these four subgroups. The OxLDL levels of SAP, UAP and AMI groups were also significantly higher than those in control group (1.13¡À0.30£© ¦Ìkat/ml£¬£¨1.23¡À0.33£© ¦Ìkat/ml and £¨1.15¡À0.32£© ¦Ìkat/ml vs £¨0.68¡À0.30£© ¦Ìkat/ml, P<0.01, but there was no significant difference among these 3 subgroups either. Multiª²variable regression analysis with the serum OxLDL level as a dependent variable indicated that the number of diseased vessels was an independent risk factor related with the serum OxLDL level(P<0.01). CONCLUSION The serum OxLDL level is a independent risk factor of the severity of CAD.

²Î¿¼ÎÄÏ×/References

£Û1£ÝSteinbrecher UP, Parthasarathy S, Leake DS, et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids£ÛJ£Ý. PNAS£¬ 1984,81(12):3883-3887.

£Û2£Ý Itabe H, Takeshima E, Iwasaki H, et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides£ÛJ£Ý. J Biol Chem, 1994,269(21):15274-15279.

£Û3£Ý Itabe H, Yamamoto H, Imanaka T, et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody£ÛJ£Ý. J Lipid Res, 1996,37(1):45-53.

£Û4£Ý Kotani K, Maekawa M, Kanno T, et al. Distribution of immunoreactive malondialdehydeª²modified lowª²density lipoprotein in human serum£ÛJ£Ý. Biochim Biophys Acta, 1994,1215(1-2):121-125.

£Û5£Ý Holvoet P, Perez G, Zhao Z, et al. Malondialdehydeª²modified low density lipoproteins in patients with atherosclerotic disease£ÛJ£Ý. J Clin Invest, 1995,95(6):2611-2619.

£Û6£Ý Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehydeª²modified LDL in patients with acute coronary syndromes and stable coronary artery disease£ÛJ£Ý. Circulation, 1998,98(15):1487-1494.

£Û7£Ý Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes£ÛJ£Ý. Circulation, 2001,103(15):1955-1960.

£Û8£Ý Kohno H, Sueshige N, Oguri K, et al. Simple and practical sandwichª²type enzyme immunoassay for human oxidatively modified low density lipoprotein using antioxidized phosphatidylcholine monoclonal antibody and antihuman apolipoproteinª²B antibody£ÛJ£Ý. Clin Biochem, 2000,33(4):243-253.

£Û9£Ý Itabe H, Suzuki K, Tsukamoto Y, et al. Lysosomal accumulation of oxidized phosphatidylcholineª²apolipoprotein B complex in macrophages: intracellular fate of oxidized low density lipoprotein£ÛJ£Ý. Biochim Biophys Acta, 2000,1487(2-3):233-245.

£Û10£Ý Van Berkel TJ, De Rijke YB, Kruijt JK. Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats£º Recognition by various scavenger receptors on Kupffer and endothelial liver cells£ÛJ£Ý. J Biol Chem, 1991,266(4):2282-2289.

±¸×¢/Memo

±¸×¢/Memo:

ÊÕ¸åÈÕÆÚ£º2005-09-20.ͨѶ×÷ÕߣºÒ׶¨»ª£¬Ö÷ÈÎҽʦ£¬½ÌÊÚ£¬Ö÷Òª´Óʸ´ÔÓÏÈÐIJ¡¡¢ÐÄÔà°êĤ²¡ÒÔ¼°ÐÄÔàÒÆÖ²·½ÃæµÄÑо¿ Tel£º(029)84775307 Email£ºyidh@fmmu.edu.cn ×÷Õß¼ò½é£º½ðÕñÏþ£¬Ö÷ÖÎҽʦ£¬²©Ê¿ Tel£º(029)83375311 Email£ºjinzx@fmmu.edu.cn

³£Óù¦ÄÜ

¸üÐÂÈÕÆÚ/Last Update: